Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 40

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 40
---
 to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.

In the ordinary course of their various business activities, the Placement Agents and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the Placement Agents or their affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The Placement Agents and their affiliates may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the Common Stock offered hereby. Any such short positions could adversely affect future trading prices of the Common Stock offered hereby. The Placement Agents and certain of their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

On July 30, 2024, we entered
into a securities purchase agreement with certain institutional and other accredited investors, pursuant to which we issued and sold
5,000,000 shares of our Common Stock in a registered direct offering and warrants to purchase 5,000,000 shares of Common Stock in a concurrent
private placement, for a combined purchase price of $2.00 per share of Common Stock and accompanying warrant. The closing of the private
placement took place on August 1, 2024 and we received total gross proceeds of $10.0 million. Brookline acted as co-placement agent and
H.C. Wainwright & Co., LLC acted as the lead placement agent, for the registered direct offering and concurrent private placement.
The placement agents were entitled to fees equal to 7.0% of the gross proceeds from the registered direct offering and concurrent private
placement.

As stated above, the Placement Agents and their respective affiliates have and may in the future provide, from time to time, investment banking and financial advisory services to us in the ordinary course of business, for which they may receive customary fees and commissions.

The foregoing does not purport